Peptides for healing and recovery is a research area built on four mechanistically distinct groups: angiogenic and cytoskeletal repair peptides, copper-carrying matrikines, anti-inflammatory melanocortin fragments, and receptor-selective cytoprotective molecules. The published evidence is heavily weighted toward rodent injury models and cell culture; human trial data is scarce and, for most of these compounds, absent entirely. This overview maps the classes onto the injury models they are actually used in, compares the compounds researchers specify most often, and sets out how a reference material is selected for a given experimental question. Every item is supplied for laboratory research use only.
What "recovery" means as a measurable endpoint
Repair studies almost never report recovery as a single figure. Depending on the tissue, published endpoints include tensile strength at failure and stiffness for tendon and ligament models, wound closure rate and re-epithelialisation percentage in excisional skin models, collagen type I to type III ratio on histology, capillary density by CD31 immunostaining, and inflammatory cytokine panels — typically TNF-α, IL-1β and IL-6. Functional endpoints such as gait analysis or grip strength appear in the better-designed rodent work.
These endpoints do not move together. A compound that accelerates wound closure may leave a mechanically weaker scar; one that raises capillary density may not change tensile strength at all. Fixing the endpoint before selecting a compound is what separates a designed experiment from a screen.
The peptide classes studied for tissue repair
Gastric pentadecapeptide BPC-157
BPC-157 is a 15-residue sequence derived from a fragment of human gastric juice protein BPC, with a molecular weight of 1419.55 Da and no known endogenous receptor. Its published mechanism is indirect: rodent work reports upregulation of VEGFR2 signalling and eNOS activity, promotion of new vessel formation in the granulation tissue, and modulation of the nitric oxide system. The animal literature is unusually broad — tendon, ligament, muscle, bone, gastrointestinal mucosa and nerve models have all been published, largely from a single research group in Zagreb over three decades. That concentration of authorship is itself a limitation researchers should note. There are no completed published human trials.
Thymosin beta-4 and the TB-500 fragment
TB-500 is not thymosin beta-4. It is the synthetic seven-residue actin-binding domain (LKKTETQ region) of the 43-amino-acid parent protein, at 889.02 Da against the parent's 4963.44 Da. The fragment retains actin sequestration and is far cheaper to synthesise; the parent protein carries additional functions the fragment does not. Studies that intend to model thymosin beta-4 biology in full should specify full-length thymosin beta-4 rather than the fragment, and papers that use the terms interchangeably are describing different molecules. Reported activity centres on cell migration, angiogenesis and reduced fibrosis in cardiac and corneal injury models.
Copper-binding matrikines
GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine complexed with copper(II), first isolated from human plasma by Loren Pickart in 1973. It is the best-documented compound in this group: gene-expression profiling work reported that GHK modulates the expression of a large fraction of the human genome in cultured fibroblasts, with effects clustering on collagen synthesis, metalloproteinase balance and antioxidant response. Because the copper ion is integral to activity, GHK-Cu handling differs from ordinary peptide handling — the complex is pH-sensitive and the free peptide is not equivalent to the complex.
Anti-inflammatory and cytoprotective peptides
KPV is the C-terminal tripeptide of α-MSH (residues 11-13), 342.43 Da, and retains the anti-inflammatory activity of the parent hormone without its melanocortin receptor pigmentation effects. Reported action is intracellular, via NF-κB pathway inhibition, which is consistent with its activity in colitis models where the peptide reaches epithelial cells. ARA-290, or cibinetide, is an 11-residue peptide designed to engage the innate repair receptor — the EPO receptor/β-common receptor heterodimer — without the erythropoietic effect of erythropoietin itself; it is one of the few compounds in this area with published human trial data, from sarcoidosis-associated small-fibre neuropathy studies.
Comparison table: compounds most specified in repair research
| Compound | Size / MW | Reported target | Best-documented model | Research sizes |
|---|---|---|---|---|
| BPC-157 | 15 aa, 1419.55 Da | No identified receptor; VEGFR2/NO pathway effects | Rodent tendon, muscle and GI mucosa | 2-20 mg |
| TB-500 | 7 aa, 889.02 Da | G-actin sequestration | Cardiac and corneal injury, cell migration assays | 2-20 mg |
| Thymosin beta-4 (full) | 43 aa, 4963.44 Da | Actin binding plus additional parent-protein activity | Dermal and cardiac repair models | 2 mg, 5 mg |
| GHK-Cu | 3 aa + Cu(II), 403.93 Da | Copper transport; broad transcriptional modulation | Fibroblast culture, dermal wound models | 10-500 mg |
| KPV | 3 aa, 342.43 Da | Intracellular NF-κB inhibition | Rodent colitis, epithelial inflammation | 5 mg, 10 mg |
| ARA-290 | 11 aa, 1259.34 Da | Innate repair receptor (EPOR/βcR) | Neuropathy models; published human trial data | 10 mg, 20 mg |
| MGF | IGF-1Ec variant, 2867.10 Da | IGF-1 receptor, local splice variant | Satellite-cell proliferation after muscle damage | 2 mg, 5 mg |
| BPC-157 + TB-500 | Co-lyophilised pair | Combined angiogenic and cytoskeletal | Fixed-ratio combination screening | 10 mg, 20 mg |
Molecular weights and sequence lengths above are the specifications of the reference molecules and match the figures published on each product page; model column entries describe where the strongest published work sits, not a claim of effect.
What the published record actually shows
Cell and tissue work
In culture the picture is reasonably consistent. GHK-Cu increases collagen and glycosaminoglycan synthesis in dermal fibroblasts across multiple independent laboratories, and the transcriptional data is the most replicated finding in this whole area. Thymosin beta-4 and its actin-binding fragment reproducibly increase keratinocyte and endothelial migration in scratch and transwell assays. KPV suppresses NF-κB-driven cytokine output in stimulated epithelial and immune cell lines. BPC-157's in-vitro record is thinner than its in-vivo record, which is an unusual pattern and one worth acknowledging in any review.
Animal models
Rodent work dominates. Transected Achilles tendon, crushed muscle, colitis and excisional skin wound models recur across the BPC-157 literature with reported improvements in tensile strength and closure rate. Thymosin beta-4 has published cardiac infarct and corneal work from several groups. ARA-290 has rodent neuropathy and islet-transplant data. The recurring methodological weaknesses across this body of work are small group sizes, inconsistent blinding, and — for BPC-157 specifically — the narrow authorship base noted above.
Human data
ARA-290 is the exception: it progressed to controlled human trials with reported changes in small-fibre function and patient-reported outcomes. GHK-Cu has controlled cosmetic and dermatological trial data in topical formulations. BPC-157, TB-500 and full-length thymosin beta-4 have no completed published efficacy trials in humans, and none of the compounds discussed here is approved for any human repair indication.
How researchers choose peptides for healing and recovery
- Which tissue and which failure mode? Vascularisation-limited models point toward the angiogenic compounds; migration-limited models toward the actin-binding peptides; inflammation-driven models toward KPV or ARA-290.
- Is a receptor needed for the readout? ARA-290 and the IGF-family reagents have defined receptors, which allows antagonist or knockout controls. BPC-157 does not, so mechanistic claims about it are harder to close.
- Local or systemic delivery? Topical and cream formats exist for the copper peptides and for BPC-157, and are the right choice where the question is confined to skin; vials are used where systemic exposure is part of the model.
- Does the ratio matter? Co-lyophilised preparations such as the KLOW blend fix the proportions between four molecules. That suits fixed-combination screening but rules out any concentration-response work on the individual components.
The complete set of compounds tagged to this goal sits in the healing and recovery collection, and the narrower mechanistic grouping is catalogued under tissue repair peptides. For the single comparison researchers ask about most, see our detailed BPC-157 versus TB-500 breakdown.
Purity, identity and handling
Short sequences such as KPV, GHK and TB-500 are synthetically straightforward and should arrive at 98% or better by HPLC with a clean mass-spectrometric identity match. BPC-157 at 15 residues is also routine. Full-length thymosin beta-4 is a different proposition: at 43 residues the synthesis is harder, deletion sequences are more likely, and the chromatogram matters more than the headline number.
GHK-Cu requires specific attention. The material should be the copper complex, not free GHK, and the characteristic blue colour of a reconstituted solution is an initial indication rather than a proof — the COA should confirm copper content. Solutions of the complex are pH-sensitive and should not be mixed with chelating buffers. Lyophilised material in this class is stored sealed at -20 °C and protected from light; reconstituted solutions are aliquoted at the point of preparation so that repeated freezing and thawing is avoided.
Formats and what each one is for
Repair peptides are supplied in more formats than any other research goal, and the format is not a cosmetic choice — it determines what question the material can answer.
Lyophilised vials remain the default. They allow the concentration to be set at reconstitution, which is a prerequisite for any concentration-response design, and they are the only format with a straightforward path from vial mass to molar concentration.
Topical creams and serums put the compound in contact with skin and dermal fibroblasts without systemic exposure. For dermal wound models and cosmetic-adjacent work this is the more relevant route, and it is the format in which GHK-Cu has controlled human data. It is the wrong format for tendon or gastrointestinal questions, where the compound will not reach the tissue in question.
Oral capsules and troches exist for BPC-157 and its arginate salt. The rationale is gastrointestinal-local exposure rather than systemic delivery: peptides of this size are substantially degraded in the gut, so an oral format is best understood as a way of putting the compound where colitis and mucosal models need it, not as an equivalent route to a vial.
Nasal sprays are pre-diluted solutions at a fixed concentration. They remove reconstitution error but fix the concentration, and they introduce a preservative and pH-adjusted vehicle that must be accounted for in any control condition.
Adjacent research families
Several compounds routinely appear alongside these in repair protocols without belonging to the same mechanistic class. PDRN, a polydeoxyribonucleotide fraction of salmon DNA, acts through adenosine A2A receptor engagement rather than any peptide mechanism. LL-37 is a cathelicidin antimicrobial peptide with reported angiogenic activity, studied mainly for host defence. VIP is a 28-residue neuropeptide with broad anti-inflammatory signalling. Grouping these with the repair peptides is a matter of shared application, not shared mechanism, and reviews that blur the distinction tend to overstate how coherent the field is.
Regulatory status
None of the peptides covered here is an approved therapy for tissue repair in the United States. BPC-157 was placed on the FDA's list of bulk substances that present significant safety risks for compounding, and it is prohibited in competitive sport under WADA rules along with TB-500 and other growth-factor-modulating agents. ARA-290 holds orphan designations but no marketing approval. GHK-Cu is used lawfully as a cosmetic ingredient in topical products; that status does not extend to injectable research material. All items referenced are research-grade, sold for in-vitro and laboratory use only, and are not for human or veterinary administration.